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Background
Over 10 years after the establishment of the National
Health Insurance Scheme (NHIS) in Ghana, the use of a
median pricing methodology for pharmaceuticals remains
a topic of debate due to its positive and negative out-
comes. Residual effects of this pricing methodology
include proliferation of low-quality medicines, irrational
medicine use, insurance fraud and other untoward out-
comes. Of particular interest is the ripple effect of this
median pricing policy on the entire pharmaceutical sys-
tem. Ghana’s pharmaceutical system has limited local
production capacity and is heavily dependent on importa-
tion. Medicine prices continue to rise and the medicine
reimbursement value constitutes an increasingly larger
proportion of overall claims values. With finite resources
allocated to the NHIS, this presents a sustainability chal-
lenge to be addressed promptly.
Methodology
During a 2015 study of the pricing policy and the system,
data were collected using the Management Sciences for
Health (MSH) qualitative assessment tool for medicine
benefit management programs. The tool was implemented
during interviews with pharmaceutical system stakeholders
in the Greater Accra, Cape Coast and Kumasi regions of
Ghana. Stakeholders from tertiary hospitals, polyclinics,
private and public pharmacies, importers/wholesalers,
Ministry of Health, professional organizations etc. were
interviewed to gather anecdotal evidence about the impact
of pricing policy. Quantitative medicine claims data for
the period July-December 2014 were also collected to ana-
lyze patterns of medicine utilization and reimbursement
values. Market dynamics, foreign exchange and medicine
prices were considered in the comparison of reimburse-
ment prices with the market value.
Results
Influential factors including importation fees, foreign
exchange, demand and supply chain challenges are not
considered in the median pricing methodology. The
NHIS pricing methodology is widely viewed as outdated,
inefficient and a contributor to delayed reimbursements,
subsequent financial crisis and a steady decline in the
availability of medicines within the system. Anecdotal
and quantitative evidence indicates the critical need for
a revised pricing policy to include the key pricing factors
in the near future.
Conslusions
As countries strive towards Universal Health Coverage
(UHC), it is critical to consider medicines in all conversa-
tions, design and planning of programs due to their clini-
cal and financial impact. Lessons learned from Ghana
include the importance of evidence-based pharmaceutical
pricing and reimbursement policies, detailed deliberation
about medicine benefits during initial UHC designs and
policy discussions and system strengthening in support of
universal health coverage plans.
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